The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Women Experience Greater Toxicity With Fluorouracil-Based Chemotherapy for Colorectal Cancer
Abstract
PURPOSE: The toxicity profile of fluorouracil (5-FU)-based chemotherapy given on 5 consecutive days at doses of 370 to 450 mg/m(2) has been well documented. A meta-analysis of six North Central Cancer Treatment Group (NCCTG) cancer control trials involving 786 patients indicated that women treated with this type of regimen experienced more severe stomatitis and leukopenia than men. After these findings, an additional meta-analysis of the toxicity profiles on five NCCTG colorectal cancer treatment trials was undertaken. METHODS: Data for 1,093 women and 1,355 men from 12 different treatment arms were included. The primary end points were the incidence of stomatitis, leukopenia, alopecia, diarrhea, nausea, and vomiting, recorded with standard National Cancer Institute common toxicity criteria. Fisher's exact test was used to compare incidence and severity across sexes, supplemented by Forrest meta-analysis plots and logistic regression. RESULTS: The incidence of four out of six toxicities studied was significantly greater for women than men; the exceptions were severe nausea and vomiting. Overall, almost half of the women compared with a third of the men experienced severe toxicity (P <.0001). Logistic regression confirmed the univariate findings while adjusting for the effects of study, dose, body mass index, and age. The differences were consistent across treatment cycles. Response rates and survival distributions were the same for both sexes. CONCLUSION: This study confirms an earlier finding that women receiving 5-FU-based chemotherapy in a 5-day bolus schedule experience toxicity more frequently and with more severity than men. These data raise the question of whether the recommended initial dose of 5-FU-based chemotherapy for women should be lower than that for men.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Predictors of Survival after Adjuvant Chemotherapy for Colon Cancer
Watanabe, T., Wu, T.-T., Catalano, P. J., Ueki, T., Satriano, R., Haller, D. G., Benson, A. B., & Hamilton, S. R. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104193441603 · Cited by 888
Poon, M. A., O'Connell, M. J., Moertel, C. G., Wieand, H. S., Cullinan, S. A., Everson, L. K., Krook, J. E., Mailliard, J. A., Laurie, J. A., & Tschetter, L. K. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.10.1407 · Cited by 887
O'Connell, M. J., Mailliard, J. A., Kahn, M. J., Macdonald, J. S., Haller, D. G., Mayer, R. J., & Wieand, H. S. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.246 · Cited by 585
(1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.11.3537 · Cited by 495
Petrelli, N., Herrera, L., Rustum, Y., Burke, P., Creaven, P., Stulc, J., Emrich, L. J., & Mittelman, A. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.10.1559 · Cited by 450
O'Connell, M. J., Laurie, J. A., Kahn, M., Fitzgibbons, R. J., Erlichman, C., Shepherd, L., Moertel, C. G., Kocha, W. I., Pazdur, R., Wieand, H. S., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.295 · Cited by 417
Poon, M. A., O'Connell, M. J., Wieand, H. S., Krook, J. E., Gerstner, J. B., Tschetter, L. K., Levitt, R., Kardinal, C. G., & Mailliard, J. A. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.11.1967 · Cited by 375
Buroker, T. R., O'Connell, M. J., Wieand, H. S., Krook, J. E., Gerstner, J. B., Mailliard, J. A., Schaefer, P. L., Levitt, R., Kardinal, C. G., & Gesme, D. H. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.1.14 · Cited by 311
Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity
Milano, G., Etienne, M. C., Pierrefite, V, Barberi-Heyob, M., Deporte-Fety, R., & Renée, N. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690098 · Cited by 275
Macintyre, S., Ford, G., & Hunt, K. (1999) · Social Science & Medicine · doi:10.1016/s0277-9536(98)00292-5 · Cited by 273
Cited by
Sex Differences in Cancer: Epidemiology, Genetics and Therapy
Kim, H.-I., Lim, H., & Moon, A. (2018) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2018.103 · Cited by 315
Let’s talk about sex: Differences in drug therapy in males and females
Madla, C. M., Gavins, F. K. H., Merchant, H. A., Orlu, M., Murdan, S., & Basit, A. W. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.05.014 · Cited by 167
Completion of therapy by Medicare patients with stage III colon cancer
Dobie, S. A., Baldwin, L.-M., Dominitz, J. A., Matthews, B., Billingsley, K., & Barlow, W. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj159 · Cited by 150
Qu, Y., Li, T., Liu, Z., Li, D., & Tong, W. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103770 · Cited by 41
Metadata
- Authors
- Sloan, J. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2002-03-15
- Volume
- 20
- Issue
- 6
- Pages
- 1491-1498
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2057975842
- Cited by
- 262
- References
- 19
- FWCI
- 6.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Women Experience Greater Toxicity With Fluorouracil-Based Chemotherapy for Colorectal Cancer. https://app.cochat.ai/papers/10.1200/jco.20.6.1491
- The paper
- Sloan, J. A. (2002). Women Experience Greater Toxicity With Fluorouracil-Based Chemotherapy for Colorectal Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.20.6.1491
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
